Eli Lilly Sales Jump 45% Amid Drug Demand Shift
Eli Lilly's sales skyrocketed by 45% thanks to the soaring demand for its weight loss drug Zepbound and diabetes treatment Mounjaro in the first quarter - however, the drugmaker has lowered its profit outlook following a recent cancer treatment deal -
